NextCure, Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The exhibits filed or furnished as part of this Quarterly Report are set forth on the Exhibit Index, below.
| Exhibit No. | | Exhibit Description |
| | | |
| 2.1† | | Agreement and Plan of Merger and Reorganization, dated as of July 14, 2026, by and among NextCure, Inc., Neptune Merger Sub Corp., Neptune Second Merger Sub, LLC and Avere Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 filed with the Company’s Current Report on Form 8-K filed on July 14, 2026). |
| | | |
| 10.1 | | Form of Avere Support Agreement (incorporated by reference to Exhibit 10.1 filed with the Company’s Current Report on Form 8-K filed on July 14, 2026). |
| | | |
| 10.2 | | Form of NextCure Support Agreement (incorporated by reference to Exhibit 10.2 filed with the Company’s Current Report on Form 8-K filed on July 14, 2026). |
| | | |
| 10.3 | | Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.4 filed with the Company’s Current Report on Form 8-K filed on July 14, 2026). |
| | | |
| 10.4 | | Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.5 filed with the Company’s Current Report on Form 8-K filed on July 14, 2026). |
| | | |
| 10.5 | | Form of CVR Agreement (incorporated by reference to Exhibit 10.6 filed with the Company’s Current Report on Form 8-K filed on July 14, 2026). |
| 10.6†† | | NextCure, Inc. Amended and Restated 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 filed with the Company’s Current Report on Form 8-K filed on June 25, 2026). |
| | | |
| 10.7*† | | Transition and Continuation Agreement, dated August 6, 2026, by and between NextCure, Inc. and LigaChem Biosciences, Inc. |
| | | |
| 10.8* | | Seventh Amendment to Lease Agreement, dated as of July 24, 2026, by and between the Company and ARE-8000/9000/10000 Virginia Manor, LLC |
| | | |
| 10.9* | | Eighth Amendment to Lease Agreement, dated as of July 29, 2026, by and between the Company and ARE-8000/9000/10000 Virginia Manor, LLC |
| | | |
| 31.1* | | Certification of Michael Richman pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| | | |
| 31.2* | | Certification of Steven P. Cobourn pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| | | |
| 32.1** | | Certification of Michael Richman and Steven P. Cobourn pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| | | |
| EX-101.INS | | Inline XBRL Instance Document |
| | | |
| EX-101.SCH | | Inline XBRL Taxonomy Extension Schema Document |
| | | |
| EX-101.CAL | | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| | | |
| EX-101.DEF | | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| | | |
| EX-101.LAB | | Inline XBRL Taxonomy Extension Label Linkbase Document |
| | | |
| EX-101.PRE | | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| | | |
| 104 | | Coverage Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
*Filed herewith.
**Furnished herewith.
†Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.
††Indicates a management contract or compensatory plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.